HCAR1 and cancer: Specifically, circulating cancer cells are exposed to lower levels of lactate (1.5–5 mM in the bloodstream), which have been reported to similarly elicit pro-tumoral behaviors, including enhanced motility, while acting through different mechanisms by binding to membrane receptors, like GPR81 [13, 25, 39–41].